



QLT Inc.

887 Great Northern Way
Vancouver, BC Canada V5T 4T5

t 604.707.7000
f 604.707.7001
www.qltinc.com

news release

QLT COMPLETES ENROLLMENT IN THE RADICAL STUDY

For Immediate Release

May 5, 2008

VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced it has completed enrolling 160 patients in the Company's Phase II RADICAL trial to determine if combination therapy with Visudyne® reduces retreatment rates compared with an anti-VEGF antibody while maintaining similar vision outcomes and an acceptable safety profile.

“The completion of enrollment in the RADICAL trial signifies that we are one step closer to our goal of having the use of Visudyne followed by Lucentis®, with or without an anti-inflammatory agent, potentially added to the product's label,” said Bob Butchofsky, President and Chief Executive Officer. “We look forward to reporting interim results in the fourth quarter of 2008 and top-line results in the first half of 2009.”

The RADICAL trial is a Phase II, multicenter, randomized, single-masked study comparing reduced-fluence Visudyne-Lucentis combination therapies and Lucentis monotherapy in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Patients are randomized to receive one of four treatments: Reduced fluence Visudyne followed by Lucentis, Reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy, Very low-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy, or Lucentis monotherapy. The duration of the trial is 24 months.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to create products such as Visudyne and Eligard® and future product opportunities. For more information, visit our web site at www.qltinc.com.

QLT Inc.:

Vancouver, Canada
Therese Hayes
Telephone: 604-707-7000 or 1-800-663-5486
Fax: 604-707-7001

The Trout Group:

New York, USA
Brandon Lewis
Telephone: 646-378-2915
or
Marcy Strickler
Telephone: 646-378-2927

Visudyne (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Lucentis is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

*Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis
Lucentis is a registered trademark of Genentech, Inc.*

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol “QLTI” and on The Toronto Stock Exchange under the trading symbol “QLT.”

Certain statements in this press release that are not historical facts constitute “forward-looking statements” of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to: our statements related to our goal of Visudyne followed by Lucentis potentially added to the product's label and our statements related to our potential reporting of Visudyne combination therapy study interim results in the fourth quarter of 2008 and top-line results in the first half of 2009 and statements which contain language such as “expects,” “will,” “plans,” “potential,” “intends,” “believes” and similar expressions that do not relate to historical matters. Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Factors that could cause actual events or results to differ materially include, but are not limited to: risks and uncertainties relating to the timing, expense and outcome of clinical trials; the timing, expense and uncertainty associated with the regulatory approval process for products; the timing and impact of existing competitive products and/or new products launched by competitors and the level of physician acceptance of Visudyne in combination with other agents); and other factors, including those described in detail in QLT's Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.